Cardiovascular Benefits of Digoxin and Empagliflozin in Patients with Chronic Heart Failure: The DIG Trial Revisited

Am J Med. 2022 Jun;135(6):670-672. doi: 10.1016/j.amjmed.2022.01.050. Epub 2022 Feb 27.

Author

Affiliation

¹ St Francis Hospital, The Heart Center, Roslyn, NY. Electronic address: Haoyi.Zheng@chsli.org.

PMID: 35235821
DOI: 10.1016/j.amjmed.2022.01.050

No abstract available

Publication types

Editorial

MeSH terms

Benzhydryl Compounds / therapeutic use
Cardiotonic Agents / therapeutic use
Clinical Trials as Topic
Digoxin* / therapeutic use
Glucosides / therapeutic use
Heart Failure* / drug therapy
Humans

Substances

Benzhydryl Compounds
Cardiotonic Agents
Glucosides
Digoxin
empagliflozin